Toxicology – Macrolide Antibiotics

Core Concept

Macrolides are antimicrobial agents used for a variety of bacterial infections. Important modern examples include:

• Azithromycin
• Clarithromycin
• Erythromycin

Older agents such as dirithromycin and troleandomycin are now rarely used or unavailable in many regions.

Isolated acute overdose is usually mild and predominantly gastrointestinal. More important toxicity often occurs during therapeutic use because of:

• QT prolongation and ventricular dysrhythmia
• Drug–drug interactions
• Hepatotoxicity
• Ototoxicity
• Exacerbation of myasthenia gravis

There is no specific antidote.

Mechanism

Macrolides inhibit bacterial protein synthesis by binding primarily to the 50S ribosomal subunit.

Toxic effects are not simply an extension of this antimicrobial mechanism.

Clinically important adverse effects involve:

• GI motility
• Cardiac repolarization
• Hepatic metabolism
• Hearing
• Neuromuscular transmission

Acute Overdose

Most isolated acute macrolide overdoses cause:

• Nausea
• Vomiting
• Abdominal pain
• Diarrhea

Severe poisoning from a single ingestion is uncommon.

Risk assessment should nevertheless consider:

• Exact macrolide
• Amount
• Symptoms
• QT-risk factors
• Electrolyte abnormalities
• Coingestants
• Drug interactions
• Underlying cardiac disease

1. Gastrointestinal Toxicity

GI effects are the most common manifestations.

Possible symptoms include:

• Nausea
• Vomiting
• Abdominal cramping
• Diarrhea

Erythromycin is particularly associated with GI effects because it can stimulate motilin receptors, increasing gastrointestinal motility.

Large fluid losses can occasionally contribute to:

• Dehydration
• Tachycardia
• Hypotension
• Electrolyte abnormalities

2. Cardiotoxicity

Several macrolides can interfere with cardiac repolarization.

The major concern is:

Potassium-channel effects → delayed ventricular repolarization → QT prolongation → torsades de pointes

This is much more important clinically than the older generic description of “ventricular dysrhythmias.”

QT Prolongation

Risk varies among individual macrolides.

Erythromycin and clarithromycin have well-recognized QT-prolonging potential.

Azithromycin can also affect cardiac repolarization, although its interaction profile differs because it has much less CYP3A4 inhibition than erythromycin or clarithromycin.

Risk Factors for Torsades

Risk increases with:

• Baseline prolonged QT
• Congenital long-QT syndrome
• Hypokalemia
• Hypomagnesemia
• Bradycardia
• Structural heart disease
• Older age
• Other QT-prolonging medications
• High systemic exposure
• Drug interactions that increase macrolide concentrations

The presence of multiple risk factors is often more important than the antibiotic alone.

Torsades de Pointes

If macrolide-associated torsades occurs:

• Stop QT-prolonging drugs
• Correct potassium
• Correct magnesium
• Correct other relevant electrolyte abnormalities
• Give IV magnesium
• Treat unstable ventricular dysrhythmia electrically

Recurrent pause-dependent torsades may require heart-rate acceleration, such as selected overdrive pacing.

Avoid adding unnecessary QT-prolonging antiarrhythmics.

ECG Assessment

Obtain an ECG when there is:

• Syncope
• Palpitations
• Significant overdose
• Known long-QT syndrome
• Significant electrolyte disturbance
• Concomitant QT-prolonging drugs
• Cardiovascular instability

Evaluate:

• Rhythm
• Heart rate
• QRS
• QT/QTc
• Ventricular ectopy

Routine prolonged monitoring is unnecessary after every minor asymptomatic ingestion.

3. Drug Interactions

Drug interactions are one of the most clinically important aspects of macrolide toxicity.

However, the older statement that all macrolides broadly inhibit hepatic metabolism is too simplistic.

Erythromycin and clarithromycin

Can significantly inhibit CYP3A4 and alter concentrations of susceptible medications.

Azithromycin

Has substantially less CYP3A4 inhibition and therefore generally causes fewer metabolism-based interactions.

Clinically Important Interactions

Depending on the specific macrolide, interactions may involve:

• Certain statins
• Some calcium-channel blockers
• Calcineurin inhibitors
• Certain benzodiazepines
• Some antiarrhythmics
• Warfarin and other anticoagulant-related therapies
• Digoxin
• Other QT-prolonging medications

The exact interaction must be checked for the individual macrolide rather than assumed to be a class effect.

Macrolides and Statins

CYP3A4-inhibiting macrolides can increase concentrations of susceptible statins.

This can increase the risk of:

• Myopathy
• Rhabdomyolysis
• Acute kidney injury secondary to severe muscle injury

Azithromycin generally has a lower interaction potential than clarithromycin or erythromycin.

Macrolides and Calcium-Channel Blockers

Some macrolides can increase exposure to CYP3A4-metabolized calcium-channel blockers.

Potential consequences include:

• Hypotension
• Bradycardia
• Acute kidney injury secondary to hemodynamic compromise

This is primarily an interaction problem rather than direct macrolide poisoning.

Macrolides and Digoxin

Some macrolides may increase digoxin exposure through mechanisms including alterations in transport and intestinal flora.

If digoxin toxicity develops, manifestations may include:

• Nausea
• Bradyarrhythmia
• AV block
• Ventricular dysrhythmia
• Hyperkalemia in severe acute poisoning

The resulting syndrome should be treated as digoxin toxicity, not simply as macrolide overdose.

4. Hepatotoxicity

Macrolides can cause liver injury.

Possible manifestations include:

• Transaminase elevation
• Cholestatic hepatitis
• Jaundice
• Rare severe hepatic dysfunction

Certain erythromycin formulations, historically especially erythromycin estolate, have been strongly associated with cholestatic liver injury.

Hepatic Evaluation

Consider:

• AST/ALT
• Bilirubin
• Alkaline phosphatase
• Coagulation studies in severe liver dysfunction

Testing is most relevant when the patient develops:

• Jaundice
• Pruritus
• Persistent vomiting
• Right-upper-quadrant symptoms
• Unexplained systemic illness

Routine liver testing is unnecessary after every small acute ingestion.

5. Ototoxicity

Macrolides can occasionally produce sensorineural hearing impairment, particularly with high systemic exposure or prolonged treatment.

Possible symptoms include:

• Tinnitus
• Reduced hearing
• Hearing distortion

Risk may increase with:

• High doses
• Renal or hepatic dysfunction
• Prolonged therapy
• Other ototoxic medications

Macrolide-associated hearing impairment is often reversible after withdrawal, although persistent deficits have occasionally been reported.

6. Myasthenia Gravis

Macrolides may impair neuromuscular transmission and can exacerbate myasthenia gravis.

Possible manifestations include:

• Ptosis
• Diplopia
• Dysphagia
• Dysarthria
• Generalized weakness
• Respiratory muscle weakness

A patient with myasthenia gravis who develops worsening weakness after starting a macrolide requires prompt assessment.

Severe respiratory weakness may require ventilatory support.

7. Infusion-Related Effects

IV erythromycin can cause:

• Local pain
• Venous irritation
• Thrombophlebitis

This is mainly a complication of parenteral therapeutic administration rather than oral overdose.

Antibiotic-Associated Diarrhea

Macrolides can alter intestinal flora.

Diarrhea during or following antibiotic treatment may simply be medication related, but persistent or severe diarrhea should raise concern for Clostridioides difficile infection.

This is an antibiotic complication rather than a direct overdose effect.

Diagnosis

Diagnosis requires identification of:

• Exact macrolide
• Formulation
• Route
• Amount
• Timing
• Symptoms
• Coingestants
• Other medications

A medication review is particularly important because a serious presentation may result from a drug interaction rather than the macrolide concentration alone.

Laboratory Evaluation

No laboratory testing may be necessary after a small, uncomplicated exposure.

For significant illness, consider:

• Glucose
• Electrolytes
• Potassium
• Magnesium
• Creatinine
• Liver tests

Additional testing depends on suspected interactions.

For example:

• CK if rhabdomyolysis is suspected
• Digoxin concentration if digoxin toxicity is suspected
• Coagulation testing when a clinically important anticoagulant interaction is suspected

Serum Macrolide Concentrations

Routine serum erythromycin, clarithromycin, or azithromycin concentrations are not useful in acute poisoning.

Clinical findings, ECG, electrolytes, organ function, and interacting medications are more useful.

Occult Coingestion

Intentional overdose warrants evaluation for clinically important coingestants.

Acetaminophen testing is often appropriate because early toxicity may be asymptomatic.

Other testing should be directed by the history and clinical presentation.

Initial Management

General priorities are:

Airway/breathing → circulation → identify exact macrolide → review interacting medications → ECG when indicated → correct electrolytes → supportive care

Most isolated acute overdoses require only symptomatic treatment.

GI Decontamination

Do not induce vomiting.

Routine gastric lavage is obsolete.

Activated charcoal may occasionally be considered after a substantial recent ingestion when:

• The exposure is potentially clinically important
• The drug is adsorbable
• The airway is safe
• Aspiration risk is low

Because most isolated macrolide overdoses are relatively benign, charcoal is unnecessary in many cases.

Vomiting and Dehydration

Persistent GI losses should be treated with:

• Appropriate oral or IV fluid replacement
• Correction of electrolyte abnormalities
• Symptomatic care

When selecting an antiemetic, consider whether it also prolongs QT in a patient already at risk for macrolide-associated QT prolongation.

Hypotension

Significant hypotension should prompt evaluation for:

• Severe dehydration
• Dysrhythmia
• Drug interaction
• Anaphylaxis
• Coingestant
• Sepsis or underlying illness

Management includes appropriate isotonic crystalloid and treatment of the underlying cause.

Persistent vasodilatory shock generally favors norepinephrine rather than the historical dopamine-first approach.

Trendelenburg positioning is obsolete.

Anaphylaxis

Although uncommon, immediate hypersensitivity can occur.

For true anaphylaxis:

Epinephrine is first-line therapy.

Airway, breathing, and circulatory support should follow standard anaphylaxis management.

Enhanced Elimination

Hemodialysis and hemoperfusion are not routinely useful for macrolide overdose.

These drugs generally have pharmacokinetic characteristics that limit meaningful extracorporeal removal.

Management remains predominantly supportive.

Monitoring

Monitoring depends on the presentation.

Minor uncomplicated exposure

Usually requires:

• Vital signs
• Symptom assessment

Significant exposure or cardiac risk

Consider:

• Continuous ECG
• Potassium
• Magnesium
• Renal function
• QT trend

Suspected interaction

Monitor the toxicity of the affected interacting drug.

Observation and Disposition

There is no universal observation period for all macrolide exposures.

Disposition depends on:

• Exact drug
• Amount
• Symptoms
• ECG
• Electrolytes
• Drug interactions
• Coingestants
• Clinical trajectory

An asymptomatic minor accidental ingestion generally does not require prolonged monitoring.

Admission

Hospitalization may be appropriate for:

• Persistent severe vomiting/dehydration
• Significant electrolyte disturbance
• Syncope with abnormal ECG
• Marked QT prolongation
• Ventricular dysrhythmia
• Significant hypotension
• Severe hepatic injury
• Severe rhabdomyolysis from a drug interaction
• Myasthenic deterioration
• Respiratory compromise

ICU care is appropriate for torsades, cardiovascular collapse, severe respiratory weakness, or other major organ dysfunction.

Pregnancy

The old FDA pregnancy letter categories are obsolete.

Antibiotic selection during pregnancy should consider:

• Specific macrolide
• Infection being treated
• Gestational stage
• Available alternatives
• Maternal and fetal risks of untreated infection

Erythromycin and azithromycin have substantial clinical experience, while individual macrolides should still be assessed separately.

Safeguarding

Rigid historical age thresholds for assuming neglect, abuse, or intentional poisoning are outdated.

Pediatric exposures should instead be evaluated according to:

• Developmental capability
• Medication accessibility
• Circumstances of exposure
• Consistency of history
• Recurrent unexplained events
• Broader safeguarding concerns

Prognosis

Most isolated acute macrolide overdoses have a favorable outcome.

Prognosis becomes more concerning when toxicity involves:

• Torsades or other ventricular dysrhythmia
• Severe electrolyte abnormalities
• Major drug interactions
• Significant hepatic injury
• Severe myasthenic weakness
• Complications of prolonged hypoperfusion or hypoxia

Ototoxicity is frequently reversible but should still be formally evaluated when clinically significant.

Important Modernization of the Older Source

• Acute isolated macrolide overdose is usually GI-predominant and relatively benign.
• QT prolongation and torsades are the major direct cardiac concerns.
• Erythromycin and clarithromycin have greater CYP3A4 interaction potential than azithromycin.
• It is inaccurate to treat all macrolides as equally potent inhibitors of hepatic drug metabolism.
• Serious toxicity frequently reflects a drug interaction rather than the antibiotic overdose itself.
• Macrolide–statin interactions can cause myopathy and rhabdomyolysis.
• Macrolide–calcium-channel blocker interactions can contribute to hypotension and AKI.
• Macrolides can exacerbate myasthenia gravis.
• Macrolide-associated hearing loss is usually reversible but can occasionally persist.
• Persistent antibiotic-associated diarrhea should raise consideration of C. difficile infection.
• Routine serum macrolide concentrations are not clinically useful.
• Ipecac and routine gastric lavage are obsolete.
• Activated charcoal is only selectively useful.
• Hemodialysis and hemoperfusion are not routine treatments.
• Trendelenburg and routine dopamine-first shock management are outdated.
• Monitoring and disposition should be based on symptoms, ECG, electrolytes, interactions, and clinical trajectory rather than a fixed observation interval.
• Historical FDA pregnancy letter categories are obsolete.

Key Points

• Macrolide overdose usually causes nausea, vomiting, abdominal pain, and diarrhea.
• Erythromycin and clarithromycin can prolong QT and cause torsades.
• Correct hypokalemia and hypomagnesemia when QT prolongation is present.
• IV magnesium is central to treatment of torsades.
• Erythromycin and clarithromycin can cause important CYP3A4-mediated interactions.
• Azithromycin generally has fewer CYP3A4 interactions but is not completely free of cardiac risk.
• Macrolides may cause cholestatic/hepatic injury, reversible ototoxicity, and worsening of myasthenia gravis.
• There is no specific antidote.
• Treatment is primarily supportive, ECG-directed, and interaction-focused.